CVS Health (CVS) Plans to Standardize Prior Authorization Processes to Ensure Seamless Patient Care
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Should l Buy CVS?
Source: seekingalpha
- Standardization of Authorization: CVS Health announced plans to align 5-10 prior authorization procedures with cross-payer clinical and technology standards by the end of 2026, which represent 40% of its total volume, ensuring patients receive uninterrupted care even when switching health plans.
- Expanded Coverage: CVS's Aetna insurance unit plans to extend this standardization to 50 of the most common prior authorization procedures under Medicare, thereby enhancing accessibility and consistency of healthcare services while minimizing service disruptions for patients across different insurance plans.
- Cost Reduction Initiatives: CEO David Joyner stated that CVS is actively reducing the number of prior authorizations, lowering hospital readmission rates and emergency room visits, and decreasing prescription drug costs, aiming to improve patient outcomes and affordability of care through these measures.
- Collaborative Policy Efforts: CVS is partnering with the Administration and Congress to deliver sensible solutions that make healthcare more affordable, demonstrating the company's strategic commitment to enhancing healthcare quality and reducing costs for patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 78.360
Low
91.00
Averages
96.71
High
105.00
Current: 78.360
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Foundayo Launch Insights Awaited Amid Sales Uncertainty
- Launch Delays: Eli Lilly's weight-loss pill Foundayo launched in the U.S. in early April, but its absence from first-quarter financials leaves investors uncertain about its market performance, with analysts suggesting initial sales may lag behind Novo Nordisk's Wegovy.
- Insufficient Sales Data: Investors generally believe that 5 to 6 weeks of prescription data are needed to accurately assess Foundayo's sales trajectory, with BMO Capital Markets analysts noting that CEO Dave Ricks' comments will be crucial, highlighting the market's focus on the new drug.
- International Market Pressure: While Lilly's Mounjaro saw sales double in India, the introduction of cheaper generic versions of Novo's Wegovy by local manufacturers is expected to pressure demand, particularly as the mix of pricing and demand for these drugs in global markets becomes a focal point for investors.
- Policy Uncertainty: The uncertainty surrounding U.S. reimbursement policies for obesity drugs has heightened investor concerns, especially following the delay of the Medicare pilot program, which may impact Lilly's pricing strategies and market share in the lucrative U.S. market.
See More
Eli Lilly's Dominance in Weight-Loss Drug Market
- Market Leadership: Eli Lilly's dominance in the weight-loss drug market positions it well for future growth, with projections indicating significant expansion over the next decade, although some investors remain skeptical about its ability to deliver superior returns in the next five years.
- Analyst Optimism: Morgan Stanley analyst Terence Flynn reiterated a 'buy' rating on Eli Lilly stock with a price target of $1,327, suggesting a potential upside of about 52% from the current price of $870, which could push the company's market cap above $1 trillion if achieved.
- Sales Potential: Flynn anticipates that Eli Lilly's newly launched weight-loss pill Foundayo, combined with Zepbound, could generate approximately $31 billion in U.S. sales next year, with projections rising to $45 billion by 2030, indicating robust revenue growth potential.
- Competition and Risks: Despite CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, Eli Lilly faces increasing competition; however, its strong pipeline in weight-loss drugs and diversification strategy should help maintain its market leadership.
See More
Analyst Sees Significant Upside for Eli Lilly Shares
- Market Leadership: Eli Lilly's dominant position in the weight-loss drug market positions it well for a bright outlook, with analysts projecting significant growth in this sector over the next decade, which is expected to drive solid medium-term growth for the company.
- Sales Growth Potential: Analysts predict that Eli Lilly's weight-loss portfolio, including the newly launched Foundayo and Zepbound, could generate approximately $31 billion in sales in the U.S. next year, potentially rising to $45 billion by 2030, indicating strong revenue growth potential.
- Competitive Risks: Despite facing pressure from competitors, particularly with CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, analysts still believe that the company's robust R&D pipeline in weight-loss drugs provides a competitive edge.
- Diversified Pipeline: Eli Lilly's extensive R&D pipeline in oncology and neuroscience, combined with its strong performance in the weight-loss market, may enhance the company's resilience against competition, further solidifying its market position.
See More
Target Stock Analysis: Potential Gains Ahead
- New CEO Reforms: Michael Fiddelke took over as CEO of Target on February 1, planning to enhance customer experience by remodeling 130 stores and launching next-day delivery in 20 new markets, thereby increasing brand appeal and market competitiveness.
- Customer Satisfaction Boost: The new store layouts have achieved a 92% customer satisfaction rate, indicating significant improvements in shopping experience, which not only attracts more customers but also enhances customer loyalty.
- Stock Price Recovery Potential: Although Target's stock has declined 37% over the past five years, it has risen approximately 33% year-to-date, indicating recovery potential, especially with a modest price-to-earnings ratio of 16 compared to Walmart's 47.
- High Dividend Appeal: With a current dividend yield of 3.5%, Target offers investors a stable cash flow, and combined with the ongoing investments, it may attract more long-term investors looking for value.
See More
SpaceX Acquires Cursor and Amazon Enters GLP-1 Market
- SpaceX Acquires Cursor: SpaceX is planning to acquire Cursor for $60 billion or pay $10 billion for collaboration, marking a significant move into the AI space, despite the complexities and potential delays associated with pre-IPO acquisitions, reflecting its ambition to transform into a tech giant.
- AI Strategic Shift: By partnering with Cursor, SpaceX aims to transition from a traditional rocket company to a tech engine that integrates space hardware with AI, addressing the significant energy and land requirements for AI computing, showcasing its long-term vision for space-based data centers.
- Amazon Enters GLP-1 Market: Amazon announced the introduction of GLP-1 medications to its platform, planning to offer same-day delivery in 4,500 cities, leveraging its robust logistics network and customer trust to disrupt traditional pharmacy markets and enhance consumer convenience in medication access.
- Competition in Healthcare: This move by Amazon could disrupt traditional pharmacies like CVS, and while challenges remain, its advantages in drug delivery and pricing strategies may attract more consumers, further solidifying its position in the healthcare sector.
See More
SpaceX Acquires Cursor, Elevating AI Strategy
- Acquisition Details: SpaceX plans to acquire Cursor for $60 billion or pay $10 billion to support collaboration, indicating its ongoing expansion in the AI sector, although this deal may impact its upcoming $2 trillion IPO.
- AI Strategy Transformation: By partnering with Cursor, SpaceX aims to transition from a traditional rocket manufacturer to a tech giant that integrates AI with space hardware, attempting to address the electricity and space requirements facing AI today.
- Market Competitive Advantage: SpaceX's goal is to establish an unmatched space infrastructure that combines powerful rockets with advanced AI technology, despite facing a $1 billion monthly burn rate in its AI division and significant technical challenges.
- Investor Confidence Test: While SpaceX's valuation reaches $2 trillion, skepticism about its commercial viability and technical feasibility persists, potentially affecting investor confidence and the success of its IPO.
See More
Eli Lilly's Foundayo Launch Insights Awaited Amid Sales Uncertainty
- Launch Delays: Eli Lilly's weight-loss pill Foundayo launched in the U.S. in early April, but its absence from first-quarter financials leaves investors uncertain about its market performance, with analysts suggesting initial sales may lag behind Novo Nordisk's Wegovy.
- Insufficient Sales Data: Investors generally believe that 5 to 6 weeks of prescription data are needed to accurately assess Foundayo's sales trajectory, with BMO Capital Markets analysts noting that CEO Dave Ricks' comments will be crucial, highlighting the market's focus on the new drug.
- International Market Pressure: While Lilly's Mounjaro saw sales double in India, the introduction of cheaper generic versions of Novo's Wegovy by local manufacturers is expected to pressure demand, particularly as the mix of pricing and demand for these drugs in global markets becomes a focal point for investors.
- Policy Uncertainty: The uncertainty surrounding U.S. reimbursement policies for obesity drugs has heightened investor concerns, especially following the delay of the Medicare pilot program, which may impact Lilly's pricing strategies and market share in the lucrative U.S. market.
See More
Eli Lilly's Dominance in Weight-Loss Drug Market
- Market Leadership: Eli Lilly's dominance in the weight-loss drug market positions it well for future growth, with projections indicating significant expansion over the next decade, although some investors remain skeptical about its ability to deliver superior returns in the next five years.
- Analyst Optimism: Morgan Stanley analyst Terence Flynn reiterated a 'buy' rating on Eli Lilly stock with a price target of $1,327, suggesting a potential upside of about 52% from the current price of $870, which could push the company's market cap above $1 trillion if achieved.
- Sales Potential: Flynn anticipates that Eli Lilly's newly launched weight-loss pill Foundayo, combined with Zepbound, could generate approximately $31 billion in U.S. sales next year, with projections rising to $45 billion by 2030, indicating robust revenue growth potential.
- Competition and Risks: Despite CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, Eli Lilly faces increasing competition; however, its strong pipeline in weight-loss drugs and diversification strategy should help maintain its market leadership.
See More
Analyst Sees Significant Upside for Eli Lilly Shares
- Market Leadership: Eli Lilly's dominant position in the weight-loss drug market positions it well for a bright outlook, with analysts projecting significant growth in this sector over the next decade, which is expected to drive solid medium-term growth for the company.
- Sales Growth Potential: Analysts predict that Eli Lilly's weight-loss portfolio, including the newly launched Foundayo and Zepbound, could generate approximately $31 billion in sales in the U.S. next year, potentially rising to $45 billion by 2030, indicating strong revenue growth potential.
- Competitive Risks: Despite facing pressure from competitors, particularly with CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, analysts still believe that the company's robust R&D pipeline in weight-loss drugs provides a competitive edge.
- Diversified Pipeline: Eli Lilly's extensive R&D pipeline in oncology and neuroscience, combined with its strong performance in the weight-loss market, may enhance the company's resilience against competition, further solidifying its market position.
See More
Target Stock Analysis: Potential Gains Ahead
- New CEO Reforms: Michael Fiddelke took over as CEO of Target on February 1, planning to enhance customer experience by remodeling 130 stores and launching next-day delivery in 20 new markets, thereby increasing brand appeal and market competitiveness.
- Customer Satisfaction Boost: The new store layouts have achieved a 92% customer satisfaction rate, indicating significant improvements in shopping experience, which not only attracts more customers but also enhances customer loyalty.
- Stock Price Recovery Potential: Although Target's stock has declined 37% over the past five years, it has risen approximately 33% year-to-date, indicating recovery potential, especially with a modest price-to-earnings ratio of 16 compared to Walmart's 47.
- High Dividend Appeal: With a current dividend yield of 3.5%, Target offers investors a stable cash flow, and combined with the ongoing investments, it may attract more long-term investors looking for value.
See More
SpaceX Acquires Cursor and Amazon Enters GLP-1 Market
- SpaceX Acquires Cursor: SpaceX is planning to acquire Cursor for $60 billion or pay $10 billion for collaboration, marking a significant move into the AI space, despite the complexities and potential delays associated with pre-IPO acquisitions, reflecting its ambition to transform into a tech giant.
- AI Strategic Shift: By partnering with Cursor, SpaceX aims to transition from a traditional rocket company to a tech engine that integrates space hardware with AI, addressing the significant energy and land requirements for AI computing, showcasing its long-term vision for space-based data centers.
- Amazon Enters GLP-1 Market: Amazon announced the introduction of GLP-1 medications to its platform, planning to offer same-day delivery in 4,500 cities, leveraging its robust logistics network and customer trust to disrupt traditional pharmacy markets and enhance consumer convenience in medication access.
- Competition in Healthcare: This move by Amazon could disrupt traditional pharmacies like CVS, and while challenges remain, its advantages in drug delivery and pricing strategies may attract more consumers, further solidifying its position in the healthcare sector.
See More
SpaceX Acquires Cursor, Elevating AI Strategy
- Acquisition Details: SpaceX plans to acquire Cursor for $60 billion or pay $10 billion to support collaboration, indicating its ongoing expansion in the AI sector, although this deal may impact its upcoming $2 trillion IPO.
- AI Strategy Transformation: By partnering with Cursor, SpaceX aims to transition from a traditional rocket manufacturer to a tech giant that integrates AI with space hardware, attempting to address the electricity and space requirements facing AI today.
- Market Competitive Advantage: SpaceX's goal is to establish an unmatched space infrastructure that combines powerful rockets with advanced AI technology, despite facing a $1 billion monthly burn rate in its AI division and significant technical challenges.
- Investor Confidence Test: While SpaceX's valuation reaches $2 trillion, skepticism about its commercial viability and technical feasibility persists, potentially affecting investor confidence and the success of its IPO.
See More
